Format

Send to

Choose Destination
Med Oncol. 2012 Mar;29(1):301-3. doi: 10.1007/s12032-010-9789-4. Epub 2010 Dec 30.

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma.

Author information

1
Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden. daniel.lindholm@medsci.uu.se

Abstract

Poorly differentiated endocrine carcinomas (PDEC) are usually treated with cisplatin-based chemotherapy regimens. We here present a case with a dramatic response (both radiologically and biochemically) to the combination of temozolomide and bevacizumab, after failure of cisplatin and etoposide, with continued tumor shrinkage at 5 months. Temozolomide combined with bevacizumab might be a good treatment option in PDEC, perhaps even in a first-line setting. Prospective studies to answer this are warranted.

PMID:
21191667
DOI:
10.1007/s12032-010-9789-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center